Irhythm Technologies Inc (NASDAQ:IRTC) saw unusually large options trading activity on Wednesday. Stock traders purchased 1,077 call options on the company. This represents an increase of approximately 926% compared to the typical volume of 105 call options.

Several research analysts have recently commented on the stock. BidaskClub lowered shares of Irhythm Technologies from a “buy” rating to a “hold” rating in a research note on Friday, October 19th. Zacks Investment Research upgraded shares of Irhythm Technologies from a “hold” rating to a “buy” rating and set a $86.00 price target on the stock in a research note on Saturday, October 27th. Canaccord Genuity restated a “buy” rating and set a $93.00 price target on shares of Irhythm Technologies in a research note on Thursday, August 2nd. Morgan Stanley increased their price target on shares of Irhythm Technologies from $86.00 to $92.00 and gave the stock an “overweight” rating in a research note on Thursday, August 2nd. Finally, BMO Capital Markets increased their price target on shares of Irhythm Technologies from $93.00 to $96.00 and gave the stock an “outperform” rating in a research note on Thursday, August 2nd. Five analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $93.13.

Shares of IRTC opened at $73.10 on Friday. Irhythm Technologies has a 12 month low of $50.37 and a 12 month high of $98.37. The firm has a market cap of $1.71 billion, a PE ratio of -56.23 and a beta of 2.03. The company has a current ratio of 4.79, a quick ratio of 4.69 and a debt-to-equity ratio of 0.51.

Irhythm Technologies (NASDAQ:IRTC) last posted its earnings results on Tuesday, October 30th. The company reported ($0.43) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.02. Irhythm Technologies had a negative net margin of 33.79% and a negative return on equity of 62.85%. The business had revenue of $38.10 million for the quarter, compared to analyst estimates of $35.87 million. During the same period last year, the business posted ($0.29) EPS. Irhythm Technologies’s revenue was up 52.2% compared to the same quarter last year. Equities research analysts forecast that Irhythm Technologies will post -1.86 earnings per share for the current fiscal year.

In other news, EVP Derrick Sung sold 10,000 shares of the stock in a transaction on Tuesday, October 16th. The shares were sold at an average price of $88.01, for a total transaction of $880,100.00. Following the transaction, the executive vice president now owns 29,458 shares in the company, valued at approximately $2,592,598.58. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Kevin M. King sold 42,832 shares of the stock in a transaction on Tuesday, November 13th. The stock was sold at an average price of $70.11, for a total transaction of $3,002,951.52. Following the transaction, the insider now owns 230,180 shares in the company, valued at approximately $16,137,919.80. The disclosure for this sale can be found here. In the last quarter, insiders sold 62,832 shares of company stock valued at $4,714,052. Insiders own 5.05% of the company’s stock.

A number of large investors have recently bought and sold shares of IRTC. Cubist Systematic Strategies LLC acquired a new position in Irhythm Technologies in the 2nd quarter valued at $101,000. Mitsubishi UFJ Securities Holdings Co. Ltd. acquired a new position in Irhythm Technologies in the 2nd quarter valued at $140,000. Great West Life Assurance Co. Can grew its stake in Irhythm Technologies by 119.9% in the 2nd quarter. Great West Life Assurance Co. Can now owns 1,979 shares of the company’s stock valued at $161,000 after buying an additional 1,079 shares during the last quarter. Prudential Financial Inc. acquired a new position in Irhythm Technologies in the 3rd quarter valued at $226,000. Finally, United Services Automobile Association acquired a new position in Irhythm Technologies in the 2nd quarter valued at $242,000.

TRADEMARK VIOLATION WARNING: “Stock Traders Buy High Volume of Irhythm Technologies Call Options (IRTC)” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of US and international copyright & trademark laws. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2018/11/16/stock-traders-buy-high-volume-of-irhythm-technologies-call-options-irtc.html.

About Irhythm Technologies

iRhythm Technologies, Inc, a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. The company offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias.

Read More: Beta

Receive News & Ratings for Irhythm Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Irhythm Technologies and related companies with MarketBeat.com's FREE daily email newsletter.